(Q44165111)

30 November 2017

title

Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation (English)

1 reference

30 November 2017

main subject

liver transplantation

1 reference

1 reference

9

1 reference

30 November 2017

Lluís Castells

1

0 references

Rafael Esteban

object named as

Rafael Esteban

10

0 references

Maria Buti

5

object named as

Maria Buti

1 reference

30 November 2017

Víctor Vargas

2

1 reference

30 November 2017

Francisco Rodríguez

3

1 reference

30 November 2017

Helena Allende

4

1 reference

30 November 2017

José F Sánchez-Avila

6

1 reference

30 November 2017

Rosendo Jardí

7

1 reference

30 November 2017

Carlos Margarit

8

1 reference

30 November 2017

Jaime Guardia

11

1 reference

30 November 2017

language of work or name

1 reference

1 October 2002

1 reference

30 November 2017

published in

Liver Transplantation

1 reference

30 November 2017

volume

8

1 reference

30 November 2017

issue

10

1 reference

30 November 2017

page(s)

892-900

1 reference

De novo and apparent de novo hepatitis B virus infection after liver transplantation.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

"Occult" hepatitis B virus as source of infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Infectivity of hepatic allografts with antibodies to hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Prevalence of hepatitis B markers in the population of Catalonia (Spain). Rationale for universal vaccination of adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Severe clinical course of de novo hepatitis B infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Hepatitis B vaccination in liver transplant candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35555

21 January 2018

Identifiers

DOI

10.1053/JLTS.2002.35555

1 reference

30 November 2017

1 reference